Catalyst
Slingshot members are tracking this event:
Sarepta (SRPT) Wins Patent Fight Against BioMarin (BMRN) for Use of Exon 51 Antisense Oligonucleotides to Treat Duchenne Muscular Dystrophy (DMD)
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 20, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Exon 51 Antisense Oligonucleotides, Duchenne Muscular Dystrophy, Exon Skipping, Uspto, Patent Trial And Appeals Board, Eteplirsen, Exondys 51
